Genocea’s GEN-009 Vaccine Demonstrates Best-in-Class Immune Responses to ATLAS™-selected Neoantigens in Cancer Patients

NEXT STORY
Myriad Genetics Announces New Results from Two Large Studies of Its myRisk® Hereditary Cancer Test at American Society of Clinical Oncology
PREV STORY
Oncology Venture receives response from the FDA to the IND-application and proposed pivotal study for LiPlaCis
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

GALAPAGOS REPORTS PRIMARY ENDPOINT FOR THE ONGOING FILGOTINIB MANTA AND MANTA-RAy SAFETY STUDIES

author_avatar
NASDAQ Market News

Castle Connolly Medical Ltd. Continues to Expand Its Database of Top Doctors Across the U.S.

New York, NY, May 15, 2018 (GLOBE NEWSWIRE) -- Castle Connolly Medical Ltd. (www.castleconnolly.com) ...

author_avatar
NASDAQ Market News

Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL

Overall response rate was 52% and median duration of response was not reached at ...

author_avatar
NASDAQ Market News